Compare AIFC & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIFC | VRCA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 88.0M |
| IPO Year | 1994 | 2018 |
| Metric | AIFC | VRCA |
|---|---|---|
| Price | $0.52 | $5.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 877.5K | 104.1K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,532,000.00 | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.36 | $3.28 |
| 52 Week High | $0.72 | $9.82 |
| Indicator | AIFC | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 47.80 |
| Support Level | $0.38 | $4.52 |
| Resistance Level | $0.63 | $5.94 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 7.10 | 43.60 |
AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.